Literature DB >> 33456658

Severe COVID-19 infection in a patient with a blastic transformation of a chronic myeloid leukemia and severe treatment-induced immunosuppression: a case report.

Louardi Mounir1,2, Simou Mehdi1,2, Fahmaoui Kawtar1,2, Mansour Akram1,2, Et-Tahir Youness1,2, Tabat Meryem1,2, Joutey Tahiri Othmane1,2, Elkhaouri Imane1,2, Ezzouine Hanane1,2, Charra Boubakar1,2, Camara Marieme2,3, Lamchahab Mouna2,3, Harrach Asmaa2,3, Quessar Asmaa2,3.   

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread across the globe, leading to the declaration of a pandemic. While most present mild symptoms, it appears as though nearly 20% of confirmed patients develop significant complications. At this time of uncertainty, we are struggling to provide appropriate care to hematological cancer patients. We need to weigh the risks and benefits of giving cancer treatment against the odds of infecting them with COVID-19. As hematological cancer patients are immunocompromised and there are high chances of exposure during hospital visits, they can get infected and outcome can be fatal. So in this case report, we intend to discuss the possible impact of the current COVID-19 pandemic on patients with acute leukaemia in terms of diagnosis, chemotherapy, and prophylactic measures. Copyright: Louardi Mounir et al.

Entities:  

Keywords:  COVID-19; Leukaemia; chemotherapy

Year:  2020        PMID: 33456658      PMCID: PMC7796834          DOI: 10.11604/pamj.supp.2020.37.34.25501

Source DB:  PubMed          Journal:  Pan Afr Med J


  3 in total

Review 1.  Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts.

Authors:  Amer M Zeidan; Prajwal C Boddu; Mrinal M Patnaik; Jan Philipp Bewersdorf; Maximilian Stahl; Raajit K Rampal; Rory Shallis; David P Steensma; Michael R Savona; Mikkael A Sekeres; Gail J Roboz; Daniel J DeAngelo; Andre C Schuh; Eric Padron; Joshua F Zeidner; Roland B Walter; Francesco Onida; Amir Fathi; Amy DeZern; Gabriela Hobbs; Eytan M Stein; Paresh Vyas; Andrew H Wei; David T Bowen; Pau Montesinos; Elizabeth A Griffiths; Amit K Verma; Alla Keyzner; Michal Bar-Natan; Shyamala C Navada; Marina Kremyanskaya; Aaron D Goldberg; Aref Al-Kali; Mark L Heaney; Aziz Nazha; Huda Salman; Selina Luger; Keith W Pratz; Heiko Konig; Rami Komrokji; Michael Deininger; Blanca Xicoy Cirici; Vijaya Raj Bhatt; Lewis R Silverman; Harry P Erba; Pierre Fenaux; Uwe Platzbecker; Valeria Santini; Eunice S Wang; Martin S Tallman; Richard M Stone; John Mascarenhas
Journal:  Lancet Haematol       Date:  2020-06-18       Impact factor: 18.959

2.  Acute leukemia in the time of COVID-19.

Authors:  Mathilde Gavillet; Jeanette Carr Klappert; Olivier Spertini; Sabine Blum
Journal:  Leuk Res       Date:  2020-03-26       Impact factor: 3.156

3.  COVID-19 in persons with haematological cancers.

Authors:  Wenjuan He; Lei Chen; Li Chen; Guolin Yuan; Yun Fang; Wenlan Chen; Di Wu; Bo Liang; Xiaoting Lu; Yanling Ma; Lei Li; Hongxiang Wang; Zhichao Chen; Qiubai Li; Robert Peter Gale
Journal:  Leukemia       Date:  2020-04-24       Impact factor: 12.883

  3 in total
  1 in total

Review 1.  What Do We Currently Know About Chronic Myeloid Leukemia (CML) and COVID-19?

Authors:  Nancy Delgado; Anahí Torres
Journal:  Curr Oncol Rep       Date:  2022-02-26       Impact factor: 5.945

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.